MP2-20 FEASIBILITY STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR PLATINUM-BASED CHEMOTHERAPY RESISTANT METASTATIC UPPER TRACT UROTHELIAL CARCINOMA PATIENTS

Abstract

You have accessJournal of UrologyBladder Cancer: Upper Tract TCC I1 Apr 2015MP2-20 FEASIBILITY STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR PLATINUM-BASED CHEMOTHERAPY RESISTANT METASTATIC UPPER TRACT UROTHELIAL CARCINOMA PATIENTS Shigetaka Suekane, Masanori Noguchi, Kousuke Ueda, Tsukasa Igawa, Tetsuro Sasada, and Kyogo Itoh Shigetaka SuekaneShigetaka Suekane More articles by this author , Masanori NoguchiMasanori Noguchi More articles by this author , Kousuke UedaKousuke Ueda More articles by this author , Tsukasa IgawaTsukasa Igawa More articles by this author , Tetsuro SasadaTetsuro Sasada More articles by this author , and Kyogo ItohKyogo Itoh More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.143AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The prognosis of metastatic upper tract urothelial carcinoma ( UTUC ) patients who failed platinum-based chemotherapy remains very poor. We conducted a feasibility study of personalized peptide vaccine ( PPV ) for platinum-based chemotherapy resistant metastatic UTUC patients to explore cancer vaccine as a new treatment modality. METHODS A total of 34 UTUC patients were enrolled to this study, who were platinum-based chemotherapy resistant metastatic 21 pelvic cancer and 13 ureter cancer. A maximum of four HLA-matched peptides showing higher antigen-specific immunoglobulin G ( IgG ) responses were selected based on measurement of IgG against different cytotoxic T lymphocyte ( CTL ) epitope peptides followed by subcutaneous vaccination. This study protocol was approved by the institutional ethical review boards of Kurume University, and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before entering this clinical trial. RESULTS There were no vaccine-related severe adverse events of PPV in all patients. Median overall survival ( OS ) time from the first PPV was 13.0 months in platinum-based chemotherapy resistant metastatic UTUC patients. Increased the anti-peptide IgG titer were revealed seventeen patients ( 50.0% ) of thirty-four patients at post 6th vaccination, and sixteen patients ( 100% ) of sixteen patients at post 12th vaccination. Seventeen patients with 12th more PPV showed significantly longer survival than 17 patients with less than 12th PPV (hazard ratio [HR], 4.775, P=0.0015). Peptide-specific immune response at 12th PPV in platinum-based chemotherapy resistant metastatic UTUC patients was favorable biomarker for OS ( P=0.0002 ), regardless of the response at 6th PPV. CONCLUSIONS PPV as a new treatment modality in patients with platinum-based chemotherapy resistant metastatic UTUC is active and well tolerated, improving survival with immune responses. Further large-scale, randomized trials are needed to confirm these results. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e18 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shigetaka Suekane More articles by this author Masanori Noguchi More articles by this author Kousuke Ueda More articles by this author Tsukasa Igawa More articles by this author Tetsuro Sasada More articles by this author Kyogo Itoh More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...